Miltenyi Biotec

MACS® GMP T Cell TransAct™

Order no. 170-076-156

Contents

1. Description

Components	1 Vial containing 4 mL MACS® GMP T Cell TransAct™
Capacity	The reagent is sufficient to activate and expand up to 2×10^8 enriched T cells or up to 4×108 PBMC in a maximal volume of 70 mL, when used at recommended titer of 1:17.5.
Product format	Polymeric nanomatrix conjugated to recombinant humanized CD3 and CD28 agonist supplied in phosphate buffered-saline (PBS), containing 0.03% poloxamer 188 and 5 g/L recombinant human serum albumin, pH 7.3–7.9
Endotoxin content	≤2 EU/vial as determined by kinetic Limulus Amebocyte Lysate (LAL) assay (Pharmacopoeia Europaea (Ph. Eur.)).
T cell proliferation assay	≥ 20% CD25/CD69 co-expression on day 2 ≥ 80% proliferating T cells on day 7
Sterility	Sterility is tested according to Ph. Eur.
Transport	At +2 °C to +8 °C (+35 °F to +46 °F)
Storage	Store protected from light at +2 °C to +8 °C (+35 °F to +46 °F). Do not freeze.
Shelf life	The use-by date is indicated on the vial label.

Disclaimer

MACS GMP Products are for *ex vivo* cell processing only, and are not intended for human *in vivo* applications.

Quality statement

MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The manufacturing and testing of this product is compliant with the requirements laid down in the Ph.Eur. Chapter 5.2.12.

The declaration of animal- or human-derived materials is given on the Certificate of Origin.

Background information

The MACS GMP T Cell TransAct has been designed to activate and expand enriched T cell populations or human resting T cells from peripheral blood mononuclear cells (PBMCs) and is provided in a format directly applicable to the CliniMACS® Prodigy.

Due to the nanoscale structure of the MACS GMP T Cell TransAct, it can be sterile filtered and excess reagent can be removed by washing. This reagent is suitable for the use in automated culture systems, such as the CliniMACS Prodigy.

2. Applications

- MACS GMP T Cell TransAct is intended for the *in vitro* stimulation and expansion of human T cells from hematological cell populations (e.g. PBMC or CD4 and CD8 enriched T cells).

3. Warnings and precautions

- The instructions for use must be followed.
- Do not inject or infuse the product directly into humans. Not for human applications.
- When using this product, the national legislation and regulations must be followed. Any application of *ex vivo* processed target cells is exclusively within the responsibility of the user.
- For single use only. Do not reuse.
- Use only if vials are undamaged and sealed.
- Do not use after the use-by date indicated on the vial label.

4. Instructions for use

4.1 Reagents and materials required

Product	Order No
MACS GMP T Cell TransAct	170-076-156
TexMACS GMP Medium – 2000mL	170-076-306
MACS GMP Recombinant Human IL-2, or equivalent	170-076-146
MACS GMP Recombinant Human IL-7, or equivalent	170-076-111
MACS GMP Recombinant Human IL-15, or equivalent	170-076-114

33881/05 | Issued: 2022-10

Miltenyi Biotec B.V. & Co. KG
Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany
+49 2204 8306-0, +49 2204 85197
macs@miltenyibiotec.de
www.miltenyibiotec.com

Miltenyi Biotec Inc.
2303 Lindbergh Street, Auburn, CA 95602, USA
800 FOR MACS, +1 530 888 8871, +1 877 591 1060
macs@miltenyibiotec.com

4.2 General notes

- Excess MACS GMP T Cell TransAct can be simply removed by a washing step, e.g. medium replacement or centrifugation followed by supernatant replacement (at least 10-fold reduction) 2–3 days after initial stimulation. Performing a washing step earlier may result in reduced T cell proliferation.
- MACS GMP T Cell TransAct has been developed in combination with TexMACS™ GMP Medium and IL-2 or IL-7 + IL-15.
- MACS GMP T Cell TransAct can be used in combination with Retro- or Lentiviral transduction. In case of lentiviral transduction it is recommended to transduce T cells 1 day after stimulation, whereas for retroviral transduction 2-3 days after stimulation.
- Presence of residual EDTA (e.g. when using CliniMACS buffer) will hamper T cell stimulation. Ensure removal (i.e. over 200-fold reduction) of EDTA prior to T cell stimulation with MACS GMP T Cell TransAct e.g. via a washing step.

4.3 Protocol

4.3.1 Fresh cell product

For stimulation of fresh PBMCs or enriched T cells a final dilution of 1:17.5 is recommended. For optimal stimulation with the CliniMACS Prodigy T cells should be activated with 1×10^6 T cells per cm^2 respectively 1.43×10^6 T cells per mL. For PBMC optimal stimulation conditions are 2×10^6 PBMC per cm^2 respectively 2.86×10^6 PBMC per mL. Minimal and maximal cell densities for the stimulation of T cells or PBMC are given below. It is recommended to use the same dilution of 1:17.5 for each condition.

Recommended cell densities for cell activation		
purified T cells	**per cm^2**	**per mL**)
minimum	**0.2×10^6**	**0.28×10^6**
optimum	**1×10^6**	**1.43×10^6**
maximum	**2×10^6**	**2.86×10^6**
PBMC	**per cm^2**	**per mL**)
minimum	**0.4×10^6**	**0.56×10^6**
optimum	**2×10^6**	**2.86×10^6**
maximum	**4×10^6**	**5.72×10^6**

**) for initial stimulation in the CliniMAC Prodigy TCT application a total of 70 mL culture medium is used

4.3.2 Frozen and thawed cell product

When working with frozen material, it is recommended to rapidly thaw the cells, wash away the freezing solution containing DMSO, resuspend the cells in culture medium at densities below 5×10^6 cells / mL and rest the cells overnight at +37 °C (+99 °F) and 5% CO_2 in culture medium. After recovery, harvest, count, resuspend and stimulate the cells as described in 4.3.1.

5. Glossary of symbols

	Manufacturer		Use-by date
REF	Order number		Phone
P/N	Part number		Fax
LOT	Batch code		E-mail
	Consult instruction for use		Website
	Do not use if package is damaged.		

This data sheet and corresponding information as well as special protocols can be found under **www.miltenyibiotec.com/170-076-156.**

Warranty

The products sold hereunder are warranted only to be free from defects in workmanship and material at the time of delivery to the customer. Miltenyi Biotec B.V. & Co. KG makes no warranty or representation, either expressed or implied, with respect to the fitness of a product for a particular purpose. There are no warranties, expressed or implied, which extend beyond the Technical Specifications of the products. Miltenyi Biotec B.V. & Co. KG's liability is limited to either replacement of the products or refund of the purchase price. Miltenyi Biotec B.V. & Co. KG is not liable for any property damage, personal injury or economic loss caused by the product.

33881/05 | Issued: 2022-10